Evidence map›Paper›PMID 42170596›Full record

ArticleJournal of human immunity2026

Good? A very long COVID-19.

Quentin Philippot, Marie-Pierre Debray, Alice Guyard, Antoine Achkar, Tom Le Voyer, Quentin Le Hingrat, Bruno Crestani, Raphaël Borie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Quentin PhilippotService de Pneumologie, Allergologie et Transplantation, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.ORCID https://orcid.org/0000-0003-3429-9605
Marie-Pierre DebrayUniversité Paris Cité, Inserm, UMR 1149, Centre de Recherche de l'Inflammation, Paris, France.ORCID https://orcid.org/0000-0003-2109-5662
Alice GuyardUniversité Paris Cité, Inserm, UMR 1149, Centre de Recherche de l'Inflammation, Paris, France.ORCID https://orcid.org/0000-0002-2406-3079
Antoine AchkarService de Pneumologie et Oncologie Thoracique, Centre Hospitalier Intercommunal Poissy Saint Germain, Poissy, France.ORCID https://orcid.org/0009-0002-2060-5245
Tom Le VoyerSt. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, New York, New York, USA, Laboratory of Human Genetics of Infectious Diseases, Inserm U1163, Paris, France.ORCID https://orcid.org/0000-0002-7253-3135
Quentin Le HingratService de Virologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.ORCID https://orcid.org/0000-0001-9017-4941
Bruno CrestaniService de Pneumologie, Allergologie et Transplantation, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-2961-3455
Raphaël BorieService de Pneumologie, Allergologie et Transplantation, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-9906-0024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of chronic SARS-CoV-2 infection resulting from impaired B cell-mediated immunity to SARS-CoV-2 in a patient with Good syndrome. Immunoglobulin replacement therapy alone was sufficient to achieve clinical and radiological resolution.

Identifiers

PMID42170596
PMCPMC13177695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.